Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 6/20 | 0.58 |
| ▸ | PPARG | P37231 | 4/20 | 0.58 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401307 | 1.00 | SLC17A5 (0.61) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL27620508 | 1.00 | SLC17A5 (0.61) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL29908094 | 1.00 | SLC17A5 (0.61) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL16634948 | 0.93 | SLC17A5 (0.57) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL29594267 | 0.93 | SLC17A5 (0.57) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL28857934 | 0.91 | PPARA (0.56) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL1738379 | 0.91 | PPARA (0.56) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL19888241 | 0.88 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL1486194 | 0.87 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3 | |
| SCHEMBL29398108 | 0.87 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| CN-112986440-A | Detection method of Fmoc-Cys (trt) -OH related substances | 吉尔多肽生物制药(大连市)有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | UNIV EMORY (US) | 2021-02-25 | — | — | US | disclosed |
| EP-1858538-B1 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS LTD (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| US-9700881-B2 | Heterocyclic coupling catalysts and methods related thereto | EMORY UNIVERSITY (US) | 2017-07-11 | — | — | US | disclosed |
| WO-2017070157-A1 | REDOX DEHYDRATION COUPLING CATALYSTS AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2017-04-27 | — | — | WO | disclosed |
| US-9598463-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | EMORY UNIVERSITY (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150274778-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. | 2015-10-01 | — | — | US | disclosed |
| US-7517855-B2 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | ATTENUON, LLC (US) | 2009-04-14 | — | — | US | disclosed |
| CN-101146545-A | Mucin hypersecretion inhibitors based on the structure of MANS and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2008-03-19 | — | — | CN | disclosed |
| EP-1858538-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060205664-A1 | Mucin hypersecretion inhibitors and methods of use | WILLIAMS, MASON L. | 2006-09-14 | — | — | US | disclosed |
| WO-2006078899-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2006-07-27 | — | — | WO | disclosed |
| CN-1741808-A | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | ATTENUON LLC (US) | 2006-03-01 | — | — | CN | disclosed |
| US-20040162239-A1 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | ATTENUON LLC | 2004-08-19 | — | — | US | disclosed |
| US-6372883-B1 | FOR THERAPY AND PROPHYLAXIS OF INFECTIONS CAUSED BY HEPATITIS C, HEPATITIS G AND HUMAN GB VIRUSES | HOFFMANN-LA ROCHE INC. | 2002-04-16 | — | — | US | disclosed |
| WO-2000050448-A1 | A METHOD FOR CONTROLLING AN ENZYMATIC REACTION BY THE ALPHA AND BETA DOMAINS OF METALLOTHIONEIN | VALLEE BERT L (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000038654-A1 | SYNTHETIC AND THERAPEUTIC METHODS FOR THE ALPHA AND BETA DOMAINS OF METALLOTHIONEIN | VALLEE BERT L (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243534-A1 | Heterocyclic Coupling Catalysts and Methods Related Thereto | HAT1, CBR3, CBR1 | SLC17A5 3864/4885PPARA 490/4885PPARG 382/4885 |
| US-20180318818-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SELENOI | SLC17A5 1789/4885PPARA 1757/4885PPARG 1819/4885 |
| US-20210053044-A1 | Redox Dehydration Coupling Catalysts and Methods Related Thereto | SCLY, TST, SQOR | SLC17A5 1940/4885PPARA 1881/4885PPARG 1930/4885 |
| US-20040162239-A1 | Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof | HDGF, VIP, PGF | SLC17A5 908/4885PPARA 3174/4885PPARG 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.